Back to Cell Types

NCI-H292Homo sapiens (Human)Cancer cell line

Also known as: NCIH292, Hut292, NCI-HUT-292, H-292, H292

🤖 AI SummaryBased on 10 publications

Quick Overview

Human mucoepidermoid carcinoma cell line with t(11;19) translocation

Detailed Summary

The NCI-H292 cell line is a human mucoepidermoid carcinoma cell line derived from a lung tumor. It is characterized by a t(11;19)(q21;p13) translocation, which results in the formation of the MECT1-MAML2 fusion gene. This fusion is associated with the disruption of Notch signaling pathways, leading to tumorigenesis. The cell line is widely used in research to study the molecular mechanisms of salivary gland cancers and the role of Notch signaling in cancer progression. It has been utilized in studies involving gene expression profiling, drug sensitivity testing, and the identification of potential therapeutic targets. The NCI-H292 cell line is also part of several large-scale cancer cell line databases, including the Cancer Cell Line Encyclopedia (CCLE) and the Catalogue of Somatic Mutations in Cancer (COSMIC).

Research Applications

Gene expression profilingDrug sensitivity testingNotch signaling pathway studiesCancer genomicsTherapeutic target identification

Key Characteristics

t(11;19) translocationMECT1-MAML2 fusion geneNotch signaling disruptionLung originPart of large cancer cell line databases

Generated on 6/15/2025

Basic Information

Database ID	CVCL_0455
Species	Homo sapiens (Human)
Tissue Source	Lymph node[UBERON:UBERON_0000029]

Donor Information

Age	32
Age Category	Adult
Sex	Female
Race	black_or_african_american

Disease Information

Disease	Lung mucoepidermoid carcinoma
Lineage	Lung
Subtype	Mucoepidermoid Carcinoma of the Lung
OncoTree Code	LUMEC

DepMap Information

Source Type	ATCC
Source ID	ACH-001075_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	NF2	p.Pro496Thrfs*8 (c.1484_1485insA)	Heterozygous	-	from parent cell line NCI-H292
Gene fusion	CRTC1	CRTC1-MAML2, MECT1-MAML2	-	In frame. CRTC1 exon 1 fused to MAML2 exon 2	PubMed=24035723

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

10

D10S1248

14,17

D12S391

16,20

D13S317

11,12

D16S539

9,13

D18S51

16

D19S433

12,13.2

D1S1656

14,15.3

D21S11

28

D22S1045

17

D2S1338

21,24

D2S441

11,12

D3S1358

16

D5S818

13

D7S820

10

D8S1179

11,14

FGA

22,26

Penta D

9

Penta E

13,15

TH01

8

TPOX

8,11

vWA

16

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

Takada M., Fukuoka M., Nakagawa K.

Cancer Res. 67:2046-2053(2007).

Multiple reciprocal translocations in salivary gland mucoepidermoid carcinomas.

Tonon G., Gehlhaus K.S., Yonescu R., Kaye F.J., Kirsch I.R.

Cancer Genet. Cytogenet. 152:15-22(2004).

t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway.

Stover K., El-Naggar A.K., Griffin J.D., Kirsch I.R., Kaye F.J.

Nat. Genet. 33:208-213(2003).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources